For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing. That…
Blog
The unseen costs of banning PBM-owned pharmacies in Tennessee
Tennessee lawmakers recently passed the FAIR Rx Act, which would bar companies from owning pharmacies while also operating a pharmacy benefit manager (PBM) and…
Blog
Trump’s State of the Union: A closer look at the claims
Last night, President Trump delivered a State of the Union address filled with optimism, applause lines, and bold claims about the country’s direction. There…
Search Posts
Washington Post
US Backs Pediatric Tests In Reversal on Drug Safety
Op-Eds
FDA Overreaches
Who could possibly oppose a pediatric-testing rule for drugs? For starters, physicians and parents who realize that while this rule is supposed to protect children,…
Washington Post
The Need to Test Drugs on Children
News Release
New York Times Attacks CEI On FDA’s Pediatric Rule
Copyright © 2002 The New York Times <?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” /> The Bush administration senselessly…
News Release
Food Expert Applauds Science Journal’s Recognition Of Flawed Mexican Corn Study
Washington, D.C., April 4, 2002-The Competitive Enterprise Institute is encouraged by an admission today from the science journal Nature that a controversial article on…
Washington Post